Sulphco Inc. (AMEX:SUF) recently reported that on September 20, 2010, the Company received notice that the NYSE Amex LLC had accepted the Company’s plan of compliance. In accepting the Company’s Plan, the Exchange granted the Company an extension until December 30, 2011 for the continued listing of the Company’s common stock and for the Company to regain compliance with the continued listing standards (the “Plan Period”) subject to quarterly progress reviews by the Exchange during the Plan Period.
Houston-based SulphCo has developed a patented safe and economic process employing ultrasound technology to alter the molecular structure of crude oil products and crude oil. The overall process is designed to “upgrade” the quality of crude oil and crude oil products by modifying and reducing the sulfur and nitrogen content to make those compounds easier to process using conventional techniques, as well as reducing the density and viscosity.
Proteonomix, Inc. (PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.
PROT recently reported further developments with its Joint Venture Company, XGEN Medical LLC (”XGen”) towards implementing operations in the United Arab Emirates.
Proteonomix is the majority shareholder in XGen with the balance held by an anonymous investor group. Proteonomix personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase.
It was further reported that XGen has expanded its talks within the region beyond a license for manufacture of and treatment with Proteonomix cellular material. Discussions are now further encompassing both the construction of XGen’s own manufacturing and treatment facility within the U.A.E. and on funding phased trials for one or more of PROT proprietary cellular materials for treatment of disease.
Additionally, the agreement calls for XGen, the joint venture, to market and distribute Proteoderm, including the Matrix NC-138 anti-aging products .
Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, http://www.proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products.
Proteonomix intends to create and dedicate a subsidiary to each of its technologies.
For more information about this company please visit http://www.proteonomix.com
China Information Technology, Inc. (NASDAQ:CNIT) a leading total solutions provider of Geographic Information Systems (GIS), digital public security and hospital information systems in China, reported on September 29, 2010 that it has been awarded a follow-on exclusive contract with the Guangdong Department of Health to provide its patented Medical Case Statistics Software (the “MCS Software”), a component of the Company’s Electronic Medical Record (EMR) system, to an additional 1,000 hospitals in Guangdong province over the next five years. This contract is an extension to the initial exclusive contract signed with the Guangdong Department of Health in 2009 which required the MCS Software to be adopted by 1,000 hospitals in Guangdong by the end of 2010. When completed, this follow-on contract will bring the total number of Guangdong hospitals that will be running on the Company’s MCS Software to 2,000.
China Information Technology, Inc., through its subsidiaries and other consolidated entities, specializes in Geographic Information System (”GIS”), digital public security and hospital information systems, with the goal of being the largest GIS software provider in China. Headquartered in Shenzhen, China, the Company’s total solutions include specialized software, hardware, systems integration, and related services organized into three business segments - Geographic Information Systems (”GIS”), Digital Information Security Technology (”DIST”), and Digital Hospital Information Systems (”DHIS”).
ULURU Inc. (AMEX:ULU) recently reported that it has signed a worldwide distribution agreement appointing Novartis the exclusive distributor of a veterinary version of Altrazeal for marketing to the animal health sector.
Under the terms of the agreement ULURU will supply Novartis with finished product for marketing in the global markets. The agreement includes other wound care products that may be developed by ULURU that the parties mutually agree to be covered by this agreement.
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup
PLEASE BE SURE TO VISIT CRWESELECT.NING.COM
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB).